MAMEDICA® Company Profile

Background

Overview

MAMEDICA® is a London-based medical cannabis clinic founded in 2021 by Jon Robson. The clinic specializes in providing cannabis-based prescription medicines to patients who have not found relief through conventional treatments. Services include remote consultations with specialist clinicians and nationwide delivery of medications.

Mission and Vision

MAMEDICA® aims to offer an alternative to conventional medicines for individuals struggling with severe medical conditions, enabling them to regain a sense of normalcy in their daily lives.

Primary Area of Focus

The clinic focuses on treating chronic and neurological conditions, including pain, anxiety, depression, ADHD, and insomnia, through personalized cannabis-based treatment plans.

Industry Significance

As one of the few UK clinics licensed to prescribe and dispense medical cannabis, MAMEDICA® plays a pivotal role in expanding access to alternative treatments within the UK's emerging medical cannabis market.

Key Strategic Focus

Core Objectives

• Patient-Centric Care: Prioritizing patient safety, security, and satisfaction through high-caliber consultants and support staff.

• Digital Healthcare Expansion: Leveraging a digital-first model to provide remote consultations and efficient medication delivery.

Specific Areas of Specialization

• Chronic Pain Management: Offering treatments for various pain-related conditions.

• Mental Health Support: Addressing issues such as anxiety, depression, and ADHD.

• Sleep Disorders: Providing solutions for insomnia and related conditions.

Key Technologies Utilized

• Telemedicine Platforms: Enabling secure video consultations between patients and clinicians.

• Supply Chain Management Systems: Ensuring efficient and compliant delivery of medical cannabis products.

Primary Markets Targeted

• United Kingdom: Serving patients across England, Scotland, Wales, and Northern Ireland.

Financials and Funding

Funding History

• Total Funds Raised: £4.5 million in a Series A funding round.

Recent Funding Round

• Date: September 2025.

• Lead Investor: Casa Verde Capital, a US-based cannabis-focused venture capital firm.

• Additional Investors: Notable figures including Premier League stars Bobby Zamora and Mark Noble, as well as strategic investors Jay Rutland and Anthony Tabatznik.

Utilization of Capital

• Supply Chain Optimization: Enhancing in-house logistics for improved efficiency and continuity of care.

• Clinical Network Expansion: Increasing the number of qualified clinicians to meet growing patient demand.

• Digital Platform Enhancement: Advancing the proprietary digital healthcare platform with enhanced automation and compliance capabilities.

• Educational Initiatives: Promoting the integration of medical cannabis into mainstream healthcare through education.

Pipeline Development

Key Pipeline Candidates

• Cannabis-Based Prescription Medicines: Developing a range of products, including dried cannabis flower for vaporization, cannabis oil extracts, and cannabis-infused edibles.

Stages of Development

• Product Development: Ongoing research and development to expand the formulary of cannabis-based medicines.

• Clinical Trials: Collaborations with licensed cultivators to ensure product quality and compliance with EU-GMP standards.

Target Conditions

• Chronic Pain: Including back and neck pain.

• Mental Health Disorders: Such as anxiety, depression, and ADHD.

• Sleep Disorders: Addressing insomnia and related conditions.

Anticipated Milestones

• Product Launches: Introduction of new cannabis-based products to the UK market.

• Regulatory Approvals: Achieving necessary certifications and approvals for new products.

Technological Platform and Innovation

Proprietary Technologies

• Digital Healthcare Platform: A secure, user-friendly system facilitating remote consultations and efficient medication delivery.

Significant Scientific Methods

• EU-GMP Compliance: Ensuring all products meet the highest manufacturing standards for quality and safety.

AI-Driven Capabilities

• Patient Data Analysis: Utilizing data analytics to personalize treatment plans and improve patient outcomes.

Leadership Team

Jon Robson: CEO and Founder. With over 18 years in financial markets, including roles at Credit Suisse and Goldman Sachs, Robson founded MAMEDICA® to provide alternative treatments for patients.

Market Overview and Competitor Analysis

Market Size and Growth Potential

The UK's medical cannabis market was valued at approximately £188 million in 2023 and is projected to exceed £470 million by 2027.

Key Competitors

• Releaf UK: A private medical cannabis clinic offering tailored treatments for chronic pain, mental health issues, and sleep disorders.

• Lyphe Clinic: Provides access to medical cannabis treatment across the UK and Channel Islands, focusing on a patient-first approach to natural wellness.

Strategic Collaborations and Partnerships

• 4C LABS Ltd.: Entered into a strategic distribution agreement to commercialize medical cannabis products under The Green Organic Dutchman brand in the UK.

• Glass Pharms: Partnered to supply high-quality cannabis flower for MAMEDICA®'s own line of medical cannabis products.

Operational Insights

Strategic Considerations

• Supply Chain Management: Optimizing logistics to ensure timely and compliant delivery of medical cannabis products.

• Clinical Network Expansion: Recruiting and training additional clinicians to meet increasing patient demand.

Competitive Advantages

• Digital-First Model: Offering remote consultations and efficient medication delivery, enhancing accessibility for patients.

• High-Quality Standards: Ensuring all products meet EU-GMP standards for quality and safety.

Strategic Opportunities and Future Directions

Strategic Roadmap

• Market Expansion: Increasing patient base and expanding services across the UK.

• Product Development: Introducing new cannabis-based products to address a broader range of medical conditions.

• Educational Initiatives: Promoting the integration of medical cannabis into mainstream healthcare through education and awareness campaigns.

Future Business Directions

• European Expansion: Leveraging the digital-first model to enter other European markets.

• Research and Development: Investing in R&D to develop innovative cannabis-based treatments.

Opportunities for Expansion

• Partnerships: Forming strategic alliances with other healthcare providers and industry leaders.

• Technology Integration: Implementing advanced technologies to enhance patient care and operational efficiency.

Contact Information

• Official Website: MAMEDICA® official website.

• Social Media:

• Twitter: @mamedicauk

• LinkedIn: MAMEDICA